^
Association details:
Biomarker:ARID1A mutation
Cancer:Colorectal Cancer
Drug:Erbitux (cetuximab) (EGFR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer

Published date:
09/19/2022
Excerpt:
Patients with ARID1A mutant-like tumors were also less likely to respond (complete or partial confirmed best response) than patients with WT-like tumors when treated with cetuximab, and the proportion of overall confirmed best response rate (ORR) was significantly lower in the ARID1A mutant-like vs. WT-like group....These data are consistent with the concept that the ARID1A mutant-like signature predicts resistance to cetuximab...
DOI:
https://doi.org/10.1038/s41467-022-33172-5
Evidence Level:
Resistant: D – Preclinical
Title:

Abstract LB-063: ARID1A mutations induce an EGFR-like gene expression signature and confer intrinsic and acquired resistance to cetuximab treatment in first line metastatic CRC

Published date:
05/15/2020
Excerpt:
...our data suggest that ARID1A loss-of-function mutations may promote resistance to cetuximab by driving an EGFR-like transcription program in the absence of ligand-dependent activation of EGFR.
DOI:
10.1158/1538-7445.AM2020-LB-063